At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 124 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
NPSP558 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism
In Brief
A Phase 3 clinical trial evaluating Placebo and NPSP558 for Hypoparathyroidism. Completed, enrolled 124 participants across 31 sites in 8 countries.
Detailed Summary
Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoparathyroidism
CountriesBelgium, Canada, Denmark, France, Hungary, Italy, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartDec 2008
Primary CompletionSep 2011
TodayJul 2026
First PostedAug 12, 2008
Enrollment StartDec 18, 2008
Primary CompletionSep 28, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago
Interventions
Placebodrug
Placebo for subcutaneous injection
NPSP558drug
Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily